Research Focus

Former Employee. Collaborative Research Centers - PIC Directed; NE Affiliate

Recent additions – View all

1. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial

   Journal Article

   Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S. M.; Reed, D. R.; Okuno, S. H.; more...
   Lancet Oncology (2013)

   Fulltext@MSK | Save
2. A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS)

   Meeting Abstract

   Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S.; Reed, D. R.; Okuno, S. H.; more...
   Journal of Clinical Oncology (2012)

   Fulltext@MSK | Save